Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by M. Heilig
Total Records ( 1 ) for M. Heilig
  J. C Umhau , R Momenan , M. L Schwandt , E Singley , M Lifshitz , L Doty , L. J Adams , V Vengeliene , R Spanagel , Y Zhang , J Shen , D. T George , D Hommer and M. Heilig
 

Context  Acamprosate is approved for the treatment of alcoholism, but its mechanism of action remains unclear. Results of animal studies suggest that a persistent hyperglutamatergic state contributes to the pathogenesis of alcoholism and that acamprosate may exert its actions by intervening in this process. Human translation of these findings is lacking.

Objective  To examine whether acamprosate modulates indices of central glutamate levels in recently abstinent alcohol-dependent patients as measured using proton nuclear magnetic resonance spectroscopy (1H-MRS).

Design  A 4-week, double-blind, placebo-controlled, randomized controlled experimental medicine study, with 1H-MRS measures obtained on days 4 and 25.

Setting  An inpatient research unit at the NIH Clinical Center.

Patients  Thirty-three patients who met the DSM-IV criteria for alcohol dependence and who were admitted for medically supervised withdrawal from ongoing alcohol use.

Intervention  Four weeks of acamprosate (initial oral loading followed by 1998 mg daily) or matched placebo, initiated at the time of admission.

Main Outcome Measures  The glutamate to creatine ratio as determined using single-voxel 1H-MRS in the anterior cingulate. Exploratory neuroendocrine, biochemical, and behavioral outcomes were also collected, as were safety- and tolerability-related measures.

Results  There was a highly significant suppression of the glutamate to creatine ratio across time by acamprosate (time x treatment interaction: F1,29 = 13.5, P < .001). Cerebrospinal fluid levels of glutamate obtained in a subset of patients 4 weeks into abstinence were uncorrelated with the MRS measures and unaffected by treatment but were strongly correlated (R2 = 0.48, P < .001) with alcohol dependence severity. Other exploratory outcomes, including repeated dexamethasone–corticotropin-releasing hormone tests, and psychiatric ratings were unaffected. Among tolerability measures, gastrointestinal symptoms were significantly greater in acamprosate-treated individuals, in agreement with the established profile of acamprosate.

Conclusion  The MRS measures of central glutamate are reduced across time when acamprosate therapy is initiated at the onset of alcohol abstinence.

Trial Registration  clinicaltrials.gov Identifier: NCT00106106

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility